Understanding the pharmacology of magic mushrooms is not just about tryptamines anymore.
Surprisingly, 4-HO-TMT has binding affinity similar to psilocin at 5-HT2A.
Understanding this is more important than ever in psychedelic research because scientists think DMT may be an endogenous neurotransmitter.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
Researchers are uncovering reasons to think there’s more to DMT than just hallucinations.
This phenomenon plays an important role in psychedelic drug research and development.
The primary active compound in this plant is more potent than LSD.
This structural analog of DMT is an understudied compound presenting new options for psychedelic drug development.
Using psychedelics to treat chronic pain is understudied yet full of potential.